285 related articles for article (PubMed ID: 11652323)
1. Medical insurance payments and patients involved in research.
Holder AR
IRB; 1994; 16(1-2):19-22. PubMed ID: 11652323
[No Abstract] [Full Text] [Related]
2. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
Fisfis BA
Duquesne Law Rev; 1993; 31(4):777-800. PubMed ID: 11652669
[No Abstract] [Full Text] [Related]
3. Funding innovative medical treatment.
Holder AR
Albany Law Rev; 1994; 57(3):795-810. PubMed ID: 11652865
[No Abstract] [Full Text] [Related]
4. Undefined experimental treatment exclusions in health insurance contracts: a proposal for judicial response.
Belk J
Wash Law Rev; 1991 Jul; 66(3):809-30. PubMed ID: 11652624
[No Abstract] [Full Text] [Related]
5. Medical necessity, AIDS, and the law.
Schultz GP; Pormenter CA
St Louis Univ Public Law Rev; 1990; 9(2):379-420. PubMed ID: 11651112
[No Abstract] [Full Text] [Related]
6. Emerging technologies and medical coverage.
Merrikin K; Smith S
Clin Ethics Rep; 1996; 10(1):9-12. PubMed ID: 11660222
[No Abstract] [Full Text] [Related]
7. Experimental drugs: more of them, but they're no longer free.
Caplan J
Hastings Cent Rep; 1987 Jun; 17(3):3. PubMed ID: 11644019
[No Abstract] [Full Text] [Related]
8. Health care providers, insurers, and individual patients; the right to treatment; economic and policy issues.
Stoddard JC; Billings PR; Astrue MJ; Tennenbaum D; Lynch EC
Suffolk Univ Law Rev; 1993; 27(4):1499-523. PubMed ID: 11657047
[No Abstract] [Full Text] [Related]
9. FDA's new rule on treatment use and sale of investigational new drugs.
Levine RJ
IRB; 1987; 9(4):1-4. PubMed ID: 11649946
[No Abstract] [Full Text] [Related]
10. Getting new drugs to people with AIDS: a public policy response to Lansdale.
Cohen MN
Hastings Constit Law Q; 1991; 18(3):471-85. PubMed ID: 11651493
[No Abstract] [Full Text] [Related]
11. National Conference on Birth, Death, and Law: report.
Andrews LB; Mariner WK;
Jurimetrics; 1989; 29(4):403-36. PubMed ID: 11652560
[No Abstract] [Full Text] [Related]
12. Surrogate consent and the incompetent experimental subject.
Bein PM
Food Drug Cosmet Law J; 1991 Sep; 46(5):739-71. PubMed ID: 11651381
[No Abstract] [Full Text] [Related]
13. Equitable access to biomedical advances: getting beyond the rights impasse.
Mariner WK
Conn Law Rev; 1989; 21(3):571-603. PubMed ID: 11650430
[No Abstract] [Full Text] [Related]
14. In business to treat cancer.
Henig RM
N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805
[No Abstract] [Full Text] [Related]
15. Secrets of the artificial heart business.
Anderson I
New Sci; 1984 Dec; 104(1433):7. PubMed ID: 11655657
[No Abstract] [Full Text] [Related]
16. Considering experimentation and elusive truth: informed consent made difficult.
Brodeur D
Issues (St Louis Mo); 1992; 7(2):1-8. PubMed ID: 11659444
[No Abstract] [Full Text] [Related]
17. The heart transplant dilemma.
Evans RW
Issues Sci Technol; 1986; 2(3):91-101. PubMed ID: 11658799
[No Abstract] [Full Text] [Related]
18. Shaking up the status quo: how AIDS activists have challenged drug development and approval procedures.
Dunbar MM
Food Drug Cosmet Law J; 1991 Sep; 46(5):673-706. PubMed ID: 11651380
[No Abstract] [Full Text] [Related]
19. Liver transplantation in Massachusetts: public policymaking as morality play.
Havighurst CC; King NM
Indiana Law Rev; 1986; 19(4):955-87. PubMed ID: 11650768
[No Abstract] [Full Text] [Related]
20. If a subject incurs obligations and carries them out, then consent is a contract: Dahl v. HEM Pharmaceuticals (Part II).
Maloney DM
Hum Res Rep; 1996 Jan; 11(1):4-5. PubMed ID: 11653221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
